Stockreport

Sanofi bets on Sino Biopharm's transplant drug in $1.5bn licensing deal [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Sanofi has taken a chance on Sino Biopharmaceutical's first-in-class, anti-inflammatory and anti-fibrotic asset, rovadicitinib, through a licensing agreement worth up t [Read more]